Could metformin or colchicine ease long COVID? major trial launches

NCT ID NCT07280572

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

The RECLAIM trial is testing whether two inexpensive, widely available drugs—metformin (a diabetes medication) and colchicine (a gout medication)—can improve quality of life for people with long COVID. The study will enroll 1,250 adults in the Netherlands who have had persistent symptoms like fatigue for at least 12 weeks after a COVID infection. Participation is fully remote, with medication delivered to homes and follow-up via online questionnaires over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
metformin and colchicine
What this could lead to
If successful, this could point toward affordable, repurposed treatments to improve physical and mental health for people with long COVID.
What could go wrong
This is an early-stage platform trial with open-label design (no placebo for some arms), so results may be biased. The drugs may not work for all long COVID symptoms, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST COVID CONDITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Netherlands

    Utrecht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.